TY - JOUR
T1 - Association of Brain Age, Lesion Volume, and Functional Outcome in Patients With Stroke
AU - Liew, Sook-Lei
AU - Schweighofer, Nicolas
AU - Cole, James H.
AU - Zavaliangos-Petropulu, Artemis
AU - Lo, Bethany P.
AU - Han, Laura K. M.
AU - Hahn, Tim
AU - Schmaal, Lianne
AU - Donnelly, Miranda R.
AU - Jeong, Jessica N.
AU - Wang, Zhizhuo
AU - Abdullah, Aisha
AU - Kim, Jun H.
AU - Hutton, Alexandre
AU - Barisano, Giuseppe
AU - Borich, Michael R.
AU - Boyd, Lara A.
AU - Brodtmann, Amy
AU - Buetefisch, Cathrin M.
AU - Byblow, Winston D.
AU - Cassidy, Jessica M.
AU - Charalambous, Charalambos C.
AU - Ciullo, Valentina
AU - Conforto, Adriana Bastos
AU - Dacosta-Aguayo, Rosalia
AU - DiCarlo, Julie A.
AU - Domin, Martin
AU - Dula, Adrienne N.
AU - Egorova-Brumley, Natalia
AU - Feng, Wuwei
AU - Geranmayeh, Fatemeh
AU - Gregory, Chris M.
AU - Hanlon, Colleen A.
AU - Hayward, Kathryn
AU - Holguin, Jess A.
AU - Hordacre, Brenton
AU - Jahanshad, Neda
AU - Kautz, Steven A.
AU - Khlif, Mohamed Salah
AU - Kim, Hosung
AU - Kuceyeski, Amy
AU - Lin, David J.
AU - Liu, Jingchun
AU - Lotze, Martin
AU - MacIntosh, Bradley J.
AU - Margetis, John L.
AU - Mataro, Maria
AU - Mohamed, Feroze B.
AU - Olafson, Emily R.
AU - Park, Gilsoon
AU - Piras, Fabrizio
AU - Revill, Kate P.
AU - Roberts, Pamela
AU - Robertson, Andrew D.
AU - Sanossian, Nerses
AU - Schambra, Heidi M.
AU - Seo, Na Jin
AU - Soekadar, Surjo R.
AU - Spalletta, Gianfranco
AU - Stinear, Cathy M.
AU - Taga, Myriam
AU - Tang, Wai Kwong
AU - Thielman, Greg T.
AU - Vecchio, Daniela
AU - Ward, Nick S.
AU - Westlye, Lars T.
AU - Winstein, Carolee J.
AU - Wittenberg, George F.
AU - Wolf, Steven L.
AU - Wong, Kristin A.
AU - Yu, Chunshui
AU - Cramer, Steven C.
AU - Thompson, Paul M.
N1 - Funding Information:
A.G. Brodtmann is supported by Australian National Health and Medical Research Council (NHMRC) GNT1020526, GNT1045617(AB), GNT1094974; Brain Foundation; Wicking Trust; Collie Trust; Sidney and Fiona Myer Family Foundation; and Heart Foundation Future Leader Fellowship 100784. C.M. Buetefisch is supported by NIH R01NS090677. W.D. Byblow is supported by the Health Research Council of New Zealand. J.M. Cassidy is supported by NIH R00 HD091375. A.B. Conforto is supported by NIH R01 NS076348; IIEP-2250-14. S.C. Cramer is supported by U01 NS120910, R01 HD095457, and R01 NR015591. A.N. Dula is supported by Lone Star Stroke Research Consortium. N. Egorova-Brumley is supported by Melbourne Research Fellowship. F. Geranmayeh is supported by Wellcome Trust (093957). L.K.M. Han is supported by a Rubicon fellowship provided by The Dutch Research Council (NWO). T. Hahn is supported by the German Research Foundation (DFG grants HA7070/2-2, HA7070/3, HA7070/4 to T.H.). B. Hordacre is supported by National Health and Medical Research Council (NHMRC) fellowship (GNT1125054). S.A. Kautz is supported by NIH P20 GM109040, 1IK6RX003075. M.S. Khlif is supported by National Health and Medical Research Council (NHMRC) grant (APP1020526). S.-L. Liew is supported by NIH R01 NS115845. B.J. MacIntosh is supported by Canadian Partnership for Stroke Recovery, Sandra E Black Centre for Brain Resilience & Recovery. M. Mataro is supported by ICREA Academia program. F. Piras is supported by Italian Ministry of Health, Ricerca Corrente, RC 21, 22. K.P. Revill is supported by NIH R01NS090677. H.M. Schambra is supported by National Institute of Neurological Disorders and Stroke (NINDS) R01 NS110696. L. Schmaal is supported by National Institute of Mental Health of the NIH (R01MH117601) and by a National Health and Medical Research Council (NHMRC) Career Development Fellowship (1140764). N. Schweighofer is supported by NIH R56 NS100528. N.J. Seo is supported by NIH/NICHD 1R01HD094731-01A1, VA RR&D I01 RX003066, U54-GM104941, and P20GM109040. S.R. Soekadar is supported by the European Research Council (ERC) grant 759370. G. Spalletta is supported by Italian Ministry of Health, RC 18-19-20-21-22/A. C.M. Stinear is supported by Health Research Council of New Zealand. M. Taga is supported by NIH R01 NS110696. G. Thielman is supported by Temple University subaward of NIH R24–NHLBI (Dr. Mickey Selzer) Center for Experimental Neurorehabilitation Training. P.M. Thompson is supported by NIH U54 EB020403. L.T. Westlye is supported by European Research Council under the European Union’s Horizon 2020 research and Innovation program (ERC StG, grant 802998), the Research Council of Norway (298646, 300767), and the South-Eastern Norway Regional Health Authority (2019101). C.J. Winstein is supported by grants HD065438 and NS100528. G.F. Wittenberg is supported by VA RR&D program, NSF, and serves on the Medical Advisory Board of Myomo, Inc., a manufacturer of rehabilitation-related equipment. S.L. Wolf is supported by VA SPiRE 1I21RX003581-01 grant 13039842; REGE19000049 NIHNIDILRR RERC Program; NIH NICHD 1R01HD095975-01A1; NINDS U01 NS102353; NINDS U01 NINDS NS166655; and NINDS1U10NS086607.
Funding Information:
A.G. Brodtmann is supported by Australian National Health and Medical Research Council (NHMRC) GNT1020526, GNT1045617(AB), GNT1094974; Brain Foundation; Wicking Trust; Collie Trust; Sidney and Fiona Myer Family Foundation; and Heart Foundation Future Leader Fellowship 100784. C.M. Buetefisch is supported by NIH R01NS090677. W.D. Byblow is supported by the Health Research Council of New Zealand. J.M. Cassidy is supported by NIH R00 HD091375. A.B. Conforto is supported by NIH R01 NS076348; IIEP-2250-14. S.C. Cramer is supported by U01 NS120910, R01 HD095457, and R01 NR015591. A.N. Dula is supported by Lone Star Stroke Research Consortium. N. Egorova-Brumley is supported by Melbourne Research Fellowship. F. Geranmayeh is supported by Wellcome Trust (093957). L.K.M. Han is supported by a Rubicon fellowship provided by The Dutch Research Council (NWO). T. Hahn is supported by the German Research Foundation (DFG grants HA7070/2-2, HA7070/3, HA7070/4 to T.H.). B. Hordacre is supported by National Health and Medical Research Council (NHMRC) fellowship (GNT1125054). S.A. Kautz is supported by NIH P20 GM109040, 1IK6RX003075. M.S. Khlif is supported by National Health and Medical Research Council (NHMRC) grant (APP1020526). S.-L. Liew is supported by NIH R01 NS115845. B.J. MacIntosh is supported by Canadian Partnership for Stroke Recovery, Sandra E Black Centre for Brain Resilience & Recovery. M. Mataro is supported by ICREA Academia program. F. Piras is supported by Italian Ministry of Health, Ricerca Corrente, RC 21, 22. K.P. Revill is supported by NIH R01NS090677. H.M. Schambra is supported by National Institute of Neurological Disorders and Stroke (NINDS) R01 NS110696. L. Schmaal is supported by National Institute of Mental Health of the NIH (R01MH117601) and by a National Health and Medical Research Council (NHMRC) Career Development Fellowship (1140764). N. Schweighofer is supported by NIH R56 NS100528. N.J. Seo is supported by NIH/NICHD 1R01HD094731-01A1, VA RR&D I01 RX003066, U54-GM104941, and P20GM109040. S.R. Soekadar is supported by the European Research Council (ERC) grant 759370. G. Spalletta is supported by Italian Ministry of Health, RC 18-19-20-21-22/A. C.M. Stinear is supported by Health Research Council of New Zealand. M. Taga is supported by NIH R01 NS110696. G. Thielman is supported by Temple University subaward of NIH R24–NHLBI (Dr. Mickey Selzer) Center for Experimental Neurorehabilitation Training. P.M. Thompson is supported by NIH U54 EB020403. L.T. Westlye is supported by European Research Council under the European Union's Horizon 2020 research and Innovation program (ERC StG, grant 802998), the Research Council of Norway (298646, 300767), and the South-Eastern Norway Regional Health Authority (2019101). C.J. Winstein is supported by grants HD065438 and NS100528. G.F. Wittenberg is supported by VA RR&D program, NSF, and serves on the Medical Advisory Board of Myomo, Inc., a manufacturer of rehabilitation-related equipment. S.L. Wolf is supported by VA SPiRE 1I21RX003581-01 grant 13039842; REGE19000049 NIH-NIDILRR RERC Program; NIH NICHD 1R01HD095975-01A1; NINDS U01 NS102353; NINDS U01 NINDS NS166655; and NINDS1U10NS086607.
Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
PY - 2023/5/16
Y1 - 2023/5/16
N2 - Background and Objectives Functional outcomes after stroke are strongly related to focal injury measures. However, the role of global brain health is less clear. In this study, we examined the impact of brain age, a measure of neurobiological aging derived from whole-brain structural neuroimaging, on poststroke outcomes, with a focus on sensorimotor performance. We hypothesized that more lesion damage would result in older brain age, which would in turn be associated with poorer outcomes. Related, we expected that brain age would mediate the relationship between lesion damage and outcomes. Finally, we hypothesized that structural brain resilience, which we define in the context of stroke as younger brain age given matched lesion damage, would differentiate people with good vs poor outcomes. Methods We conducted a cross-sectional observational study using a multisite dataset of 3-dimensional brain structural MRIs and clinical measures from the ENIGMA Stroke Recovery. Brain age was calculated from 77 neuroanatomical features using a ridge regression model trained and validated on 4,314 healthy controls. We performed a 3-step mediation analysis with robust mixed-effects linear regression models to examine relationships between brain age, lesion damage, and stroke outcomes. We used propensity score matching and logistic regression to examine whether brain resilience predicts good vs poor outcomes in patients with matched lesion damage. Results We examined 963 patients across 38 cohorts. Greater lesion damage was associated with older brain age (β = 0.21; 95% CI 0.04–0.38, p = 0.015), which in turn was associated with poorer outcomes, both in the sensorimotor domain (β = -0.28; 95% CI -0.41 to -0.15, p < 0.001) and across multiple domains of function (β = -0.14; 95% CI -0.22 to -0.06, p < 0.001). Brain age mediated 15% of the impact of lesion damage on sensorimotor performance (95% CI 3%–58%, p = 0.01). Greater brain resilience explained why people have better outcomes, given matched lesion damage (odds ratio 1.04, 95% CI 1.01–1.08, p = 0.004). Discussion We provide evidence that younger brain age is associated with superior poststroke outcomes and modifies the impact of focal damage. The inclusion of imaging-based assessments of brain age and brain resilience may improve the prediction of poststroke outcomes compared with focal injury measures alone, opening new possibilities for potential therapeutic targets.
AB - Background and Objectives Functional outcomes after stroke are strongly related to focal injury measures. However, the role of global brain health is less clear. In this study, we examined the impact of brain age, a measure of neurobiological aging derived from whole-brain structural neuroimaging, on poststroke outcomes, with a focus on sensorimotor performance. We hypothesized that more lesion damage would result in older brain age, which would in turn be associated with poorer outcomes. Related, we expected that brain age would mediate the relationship between lesion damage and outcomes. Finally, we hypothesized that structural brain resilience, which we define in the context of stroke as younger brain age given matched lesion damage, would differentiate people with good vs poor outcomes. Methods We conducted a cross-sectional observational study using a multisite dataset of 3-dimensional brain structural MRIs and clinical measures from the ENIGMA Stroke Recovery. Brain age was calculated from 77 neuroanatomical features using a ridge regression model trained and validated on 4,314 healthy controls. We performed a 3-step mediation analysis with robust mixed-effects linear regression models to examine relationships between brain age, lesion damage, and stroke outcomes. We used propensity score matching and logistic regression to examine whether brain resilience predicts good vs poor outcomes in patients with matched lesion damage. Results We examined 963 patients across 38 cohorts. Greater lesion damage was associated with older brain age (β = 0.21; 95% CI 0.04–0.38, p = 0.015), which in turn was associated with poorer outcomes, both in the sensorimotor domain (β = -0.28; 95% CI -0.41 to -0.15, p < 0.001) and across multiple domains of function (β = -0.14; 95% CI -0.22 to -0.06, p < 0.001). Brain age mediated 15% of the impact of lesion damage on sensorimotor performance (95% CI 3%–58%, p = 0.01). Greater brain resilience explained why people have better outcomes, given matched lesion damage (odds ratio 1.04, 95% CI 1.01–1.08, p = 0.004). Discussion We provide evidence that younger brain age is associated with superior poststroke outcomes and modifies the impact of focal damage. The inclusion of imaging-based assessments of brain age and brain resilience may improve the prediction of poststroke outcomes compared with focal injury measures alone, opening new possibilities for potential therapeutic targets.
UR - https://www.scopus.com/pages/publications/85160285163
UR - https://www.ncbi.nlm.nih.gov/pubmed/37015818
UR - https://www.scopus.com/pages/publications/85160285163
U2 - 10.1212/WNL.0000000000207219
DO - 10.1212/WNL.0000000000207219
M3 - Article
C2 - 37015818
SN - 0028-3878
VL - 100
SP - E2103-E2113
JO - Neurology
JF - Neurology
IS - 20
ER -